Cipher Seeks Meeting With FDA To Discuss Tramadol “Approvable” Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency asks for additional efficacy trial for the extended-release opioid analgesic.
You may also be interested in...
Cipher Submits New Tramadol NDA
Move could trigger legal action over patents, the company warns.
Cipher Submits New Tramadol NDA
Move could trigger legal action over patents, the company warns.
FDA Rejects Labopharm Appeal On Once-Daily Tramadol
Canadian drug maker says it plans to appeal to the next supervisory level at the FDA.